Back ZF2001 Arabic Zifivax Catalan ZF2001 Czech ZF2001 French ZF2001 ID ZF2001 Italian ZF2001 Malay ZF2001 Portuguese Вакцина Zifivax против COVID-19 Russian ZF2001 Ukrainian
 Logo | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Zifivax |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences.[1][2] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.[3][4]
ZF2001 employs technology similar to other protein-based vaccines[5] in Phase III trials from Novavax, Vector Institute, and Medicago.[6]
ZF2001 was first approved for use in Uzbekistan and later China.[7][8] Production capacity is expected to be one billion doses a year in China[9] and 200 million in Uzbekistan.[10] By July, 100 million doses had been administered in China and Uzbekistan.[11]
- ^ "Anhui Zhifei Longcom: RBD-Dimer – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 27 December 2020.
- ^ "COVID-19 Vaccine: ZIFIVAX by Anhui Zhifei Longcom Biopharma, Institute of Microbiology Chinese Academy of Sciences". covidvax.org. Archived from the original on 30 January 2021. Retrieved 27 December 2020.
- ^ "Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials". South China Morning Post. 20 November 2020. Retrieved 27 December 2020.
- ^ Ying TP (7 December 2020). "MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times". NST Online. Retrieved 27 December 2020.
- ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- ^ Zimmer C, Corum J, Wee SL (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 27 December 2020.
- ^ Cite error: The named reference
:6was invoked but never defined (see the help page). - ^ Cite error: The named reference
:5was invoked but never defined (see the help page). - ^ Cite error: The named reference
:7was invoked but never defined (see the help page). - ^ "ZF-UZ-VAC-2001 vaccine to be produced in Uzbekistan". UzDaily.uz (in Russian). Retrieved 28 July 2021.
- ^ Liu R (17 July 2021). "China Zhifei's COVID shot largely retains effect against Delta variant-lab study". Reuters. Retrieved 17 July 2021.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search